본문 바로가기

Refractory brainstem encephalitis mimicking progressive cerebral infarction: infliximab and methotrexate as a salvage immunotherapy

문서 유형
연구출판물 · 학술지 논문
등재
KCIScopus
저널 순위
KCI Q3
저널
Journal of Neurocritical Care14(1) · pp.46 · 2021
피인용
Scopus 0KCI 0
FWCI (Scopus)
0
ISSN
2508-1349

저자

  1. 안성호제1저자Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
  2. 노지은Department of Radiology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
  3. 우경남Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
  4. 김현성Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
  5. 박민규Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
  6. 박경필Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
  7. 백승국Department of Radiology, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, Republic of Korea
  8. 신진홍교신저자Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, Republic of Korea

초록

Background: Brainstem encephalitis is a rare, severe, and potentially life-threatening inflammation of the central nervous system, exhibiting various treatment responses and outcomes owing to multiple etiologies. Case Report: We describe the favorable outcome of salvage immunotherapy using a combination of infliximab and methotrexate in a 62-year-old woman with refractory brainstem encephalitis. The patient was initially presumed to be at a subacute stage of medullary infarction but showed progressively worsening conditions involving cervical myelopathy, despite having completed the schedule of subsequent immunotherapy with intravenous methylprednisolone, immunoglobulin, and rituximab. After completion of four sessions of weekly rituximab injection, she was treated with 5 mg/kg of infliximab, scheduled at 0, 2, and 6 weeks, along with methotrexate (weekly 12.5 mg). After completion of infliximab injection and maintenance with methotrexate treatment, she showed an improving course of quadriplegia. Conclusion: This case report provides evidence for the potential efficacy of infliximab with methotrexate in cases of refractory brainstem encephalitis.

키워드

Brainstem encephalitisSubacute cerebral infarctionInfliximabImmunotherapy

식별자

Scopus EID
2-s2.0-85121057983
KCI
ART002730757